Treatment to reduce bone fractures also improves breast cancer survival in postmenopausal people
Full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30862-3/fulltext
A large study looked at the effects of adding the bone-protective drug denosumab (Prolia), to standard hormone therapy for the treatment of early-stage, postmenopausal, HR-positive breast cancer. The researchers found that adding denosumab to aromatase inhibitor hormonal therapy improved bone health, disease-free survival and overall survival. (Posted 2/27/23)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- How do my cancer treatments affect my bone health?
- I am on an AI; should I have a bone density test?
- What do the results of my bone density test mean?
- As a postmenopausal woman with HR+ breast cancer, would denosumab be a good addition to my current cancer treatment?
- If denosumab is not a good option for me, are there other therapies or approaches that will help maintain my bone health during therapy?
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.